ANX005 shows good tolerability and evidence of response in HD

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Sep 16 / Springer Healthcare

ANX005 shows good tolerability and evidence of response in HD

Neuroscience Huntington's Disease EHDN-2022

Description

Rajeev Kumar reports the findings of a phase 2 study of the humanized monoclonal antibody ANX005 showing good tolerability, full target engagement, and predictors of response.

Follow us here

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.